Pertinent Pain Management Principles

Pain Is Subjective
First and foremost, when caring for a person in pain, it is important to remember that pain is a subjective experience. Self-report is the gold standard for rating pain and its impact on the individual's life. In addition to the body structures involved, such things as the person's previous experiences with pain, current life stress, and personality all affect the experience of pain. The subjective report of pain may or may not correlate with the history and physical or other objective measures. There is no neurophysiological or laboratory test to measure pain. 1 
Pain Vocabulary
The International Association for the Study of Pain has defined pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage." 1 Another widely recognized definition of pain is "pain is whatever the experiencing person says it is, existing whenever s/he says it does." tissue) or visceral organ process stimuli from damaged tissues. Nociceptive pain indicates that the nervous system is functioning normally. A brief overview of the basic process involved in nociceptive pain is presented in Figure 1 . Neuropathic pain results from a damaged or traumatized nervous system, either peripheral or central in origin. This type of pain is poorly understood, and in some cases no physical reason can be found to correlate with the report of pain. 3 Another common distinction is between acute and chronic pain. Using a temporal definition, acute pain exists for a shorter period (days to months) than chronic pain. Acute pain actually serves a purpose by prompting the individual to seek help to relieve the pain. In general, acute pain is well localized, responds well to therapy, and the level of pain decreases as the body heals or the treatment removes the source of pain. Acute pain that is not well managed may become chronic. Chronic pain exists beyond the time frame expected by the injury, does not serve any purpose to the body, becomes very resistant to therapy, and becomes very difficult to classify and treat. 4 Chronic pain may exist in the absence of any physical reason that supports the subjective report of pain.
Barriers to Effective Pain Management
In 1994, the Agency for Health Care Policy and Research published the Clinical Practice Guideline for the Management of Cancer Pain. The expert panel that authored this guideline delineated the barriers to effective pain management 5 (Table 1) . These barriers continue to exist, and can be generalized to pain other than that from cancer. 2 One of the most prevalent barriers to effective pain management is the fear of addiction. Both healthcare providers and patients note this concern. To address this issue, experts from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine developed the following definition:
Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. 6 Addiction needs to be differentiated from physical dependence and tolerance. Most pain specialists agree that patients treated with prolonged opioid therapy develop physical dependence and may develop tolerance. 6 True addiction is rare in those with persistent pain syndromes, especially when compared to the issue of undertreating debilitating pain. 7 As chronic pain is associated with great economic and societal costs, pain experts believe opioids are an essential part of a chronic pain management plan. 8 The safety of such therapy has been supported. [9] [10] [11] [12] [13] However, there remains controversy in the professional community about treating chronic, noncancer pain with opioid therapy. The debate encompasses other outcomes in addition to pain relief, such as restoration of function, return to work, and the concept of suffering. Some believe that current evidence is lacking, and that further study is needed to evaluate the benefits versus the costs of opioid therapy. 14 For clarification on this very complex issue, the American Academy of Pain Medicine and the American Pain Society have issued a joint statement titled The Use of Opioids for the Treatment of Chronic Pain. 8 This statement is intended to serve as a guide for both practitioners and regulators with regard to the judicious use of opioids, and addresses many common fears and misconceptions. One of the main points of this document is that opioids do have a place in chronic pain management.
Pain Assessment
In 1999, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) published standards on pain management. 15 Pain management, and appropriate pain management, is now considered a patient right. In fact, legal precedent has been established for denying this right. 16 Solid pain management starts with a solid pain assessment. Many screening tools exist, including a numerical scale that requires the patient to rate the pain using a range, typically 0 to 10, or a "Faces" scale that asks the patient to choose from a series of faces, varying from happy to sad or crying. Words may be used with any of the scales, and a corresponding pain score is obtained. When a patient is nonverbal, pain behaviors such as crying, splinting, rocking, or guarding may occur.
If pain is present on screening, a comprehensive assessment should be completed, recognizing that pain is multidimensional and includes physical, emotional, and spiritual aspects. This assessment may vary somewhat depending upon the situation but should include the location of the pain, intensity, quality, temporal characteristics (onset, duration, variations, rhythms), manner of expressing pain, what relieves the pain, what causes the pain, and the effects of pain (quality of life, function, sleep, etc). There are also mnemonics that can be used to structure this assessment when a written tool is not used, such as the word PAIN (Table 2) . A physical examination would include gait, strength, range of motion, and sensory and motor function. Special tests for specific joints or body parts have been developed and are used by pain specialists. 17 Details of this level of physical examination are beyond the scope of this article.
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Pain Treatment
Nonpharmacologic Treatment
Several nonpharmacologic interventions for chronic pain have been shown to work well alone or in combination with appropriate pharmacologic strategies. 5 These options are usually grouped under physical modalities and psychosocial interventions. When using these interventions, one needs to consider the condition of the patient and caregivers, factors such as fatigue and immobility, environmental obstacles, and other disease conditions that may influence which nonpharmacological interventions are appropriate to include in the pain management plan.
Under physical modalities, the application of heat or cold is a common intervention. Superficial heat increases blood flow to inactive tissues and increases oxygen and nutrient delivery to damaged tissues through vasodilation. It also decreases joint stiffness by increasing the elastic properties of muscles. Cold therapy reduces inflammation and edema. It is contraindicated in vasoconstrictive conditions, such as peripheral vascular disease. Another physical modality is exercise. Patients should be encouraged to remain active and participate in self-care when possible. Prolonged immobilization should be avoided to prevent deleterious effects, especially cardiovascular deconditioning. 5 The use of psychosocial interventions does not imply that the patient's pain is not real. These interventions help the patient gain a sense of control by influencing how one interprets events and bodily sensations. Cognitive techniques give patients information about the pain, helping them to think differently about the pain. Behavioral techniques help patients develop skills to cope with and modify reactions to pain. These interventions require practice, training, and self-motivation. Examples of these interventions are relaxation, imagery, distraction, reframing, hypnosis, and individual and support group therapy. 5 Several of these interventions are listed in Table 3 and should be included in any chronic pain management plan. There have been no known studies specifically targeting these interventions in HF; however, it is likely that HF patients would benefit from some of these therapies. These interventions have been extensively described in the literature; clinicians are encouraged to seek out references that detail the research on these therapies and the skills needed to incorporate them into practice. For detail on these interventions, consult references 5, 7, 18-21.
Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacologic intervention frequently used in pain management. However, there is a potential danger of this device interfering with the functions of implanted pacemakers and internal cardioverter defibrillators (ICDs). Shade reported a case study of a successful, safe use of TENS in a patient with a pacemaker. 22 TENS therapy in patients with ICDs may be associated with an increased risk of inappropriate shocks due to device interactions. 23 In a pilot study, Crevenna et al described electromagnetic interference that occurred in 3 of 8 ICD patients receiving TENS therapy. 24 These authors recommended individualized assessments for patients with ICDs who are considering TENS therapy.
Pharmacologic Treatment
Pharmacotherapy is the most common treatment used to control pain, but is also the one that requires the most attention to balancing risks and benefits. Greater reductions in pain and improvements in functional abilities are usually obtained by combining One strategy that lists both of these approaches in order of invasiveness is shown in Table 4 .
The analgesics used to treat pain are usually grouped in the nonopioid, opioid, and adjuvant group. Nonopioids include acetaminophen and NSAIDs. Opioids include drugs that bind to the opioid receptor sites in the body, such as morphine, fentanyl, methadone, and codeine. Adjuvants are medications that were developed for other uses, but have been found to be very useful in pain management, such as anticonvulsants, tricyclic antidepressants (TCAs), anesthetics, corticosteroids, and ␣ 2 -adrenergic agonists.
In the early 1980s, the World Health Organization proposed a treatment strategy for cancer pain that incorporated the use of nonopioids, opioids, and adjuvant medications. The choice of drug class is based on a pain rating of mild, moderate, or severe (Fig 2) . Mild pain (1-3 on a 0-10 scale) is treated with nonopioids (acetaminophen and NSAIDs). Moderate pain (4-6 on a 0-10 scale) is treated with the "weak opioids" (combination opioid/nonopioid preparations such as acetaminophen/oxycodone preparations). Severe pain (7ϩ on the 0-10 scale) is treated with "strong" opioids (morphine, oxycodone, fentanyl, methadone). Adjuvants as well as nonpharmacologic therapies are appropriate at any stage of the ladder.
Issues Related to Opioid Use
Patients with chronic pain may indeed need an opioid for pain management. The American Geriatric Society has noted in its guidelines that the chronic use of opioids for persistent pain may have fewer lifethreatening risks than does the long-term daily use of high-dose NSAIDs. 7 Managing Noncardiac Pain in Heart Failure Patients S79 25 Detail on the choices of opioid analgesia are beyond the scope of this article. Equianalgesia charts are helpful when choosing, titrating, and switching opioid medications ( Table 5 ). Note that although the same drugs may be used for Steps 2 and 3 on the WHO ladder, different dosing would be used for moderate versus severe pain. For the elderly, it is recommended to start with low doses and titrate up slowly. Scheduled dosing is important for continuous pain. An "as needed" dosing regimen should be used for intermittent pain.
Continuous opioid use can result in physical dependence, but this can be managed through judicious use of medications and by gradually reducing the dose once the need for opioids no longer exists. 7 Drug addiction, however, is rare, and if patients need higher dosing for relief, suspect that the underlying cause of the pain is worsening.
A key teaching point with opioid therapy is that side effects are manageable. Nausea, vomiting, and sedation will usually subside with time; constipation will always be a problem. Patients on chronic opioid therapy need a bowel management plan that includes both a stimulant and a stool softener (eg, senna plus docusate).
There are several drugs that are not good choices for managing acute or chronic pain. 1 Mixed agonistantagonists (butorphanol, nalbuphine, pentazocine) have ceiling doses and are not recommended for severe, escalating pain. If used in combination with mu-receptor agonists, these drugs may reverse analgesia and precipitate withdrawal in opioid-dependent patients. 2 Propoxyphene has efficacy similar to aspirin or acetaminophen, costs more than codeine products, and has the potential for drug accumulation, neuroexcitatory effects, ataxia, and dizziness. 3 Meperidine has an active metabolite, normeperidine, that is twice as potent as a convulsant and one half as potent as an analgesic as the parent compound. Accumulation of the metabolite with repetitive dosing can result in central nervous system excitability such as tremor, myoclonus, delirium, and seizures. Further, naloxone does not reverse meperidine-induced seizures. 26 Alternatively, tramadol is becoming a more frequent choice for management of mild to moderate pain. It is a unique analgesic in that it binds to the mu-receptor as well as inhibits norepinephrine and serotonin reuptake. Inhibition of norepinephrine and serotonin uptake adds significantly to analgesia because of inhibition of the transmission of nociceptive impulses at the spinal level. Tramadol's efficacy and safety are reported to be similar to equianalgesic doses of codeine and hydrocodone. It should be used with caution in those patients with a history of seizure disorders or those taking other medications that lower the seizure threshold. Methadone is being used more in chronic pain management, especially for neuropathic pain and to slow the development of opioid tolerance. 7 Ventricular arrhythmias have been reported in patients treated with high doses of methadone. 27, 28 It is unknown if the use of this drug in HF patients should be reserved for those patients with ICDs. Methadone is gaining respect as a powerful tool for pain management in the hospice and palliative care settings; however, it should only be prescribed and titrated by pain management specialists or clinicians familiar with this drug's unique properties.
Treating Pain in Heart Failure Patients
Although HF specialists do not have pain management as their focus, patients frequently complain of pain, and thus proper assessment is warranted. The patient may simply need a reminder to follow up with their primary provider; however, many patients need an immediate intervention and/or a change in their current treatment plan. Ongoing communication among the usual multiple providers caring for these patients is critical for keeping the treatment plan as safe and effective as possible.
Treating pain in HF patients requires modification of the WHO ladder model. Modifications are necessary because HF patients should avoid the use of NSAIDs and corticosteroids-common medicines used in treating pain, especially inflammatory pain such as occurs with arthritis. NSAIDs inhibit the enzymes cyclooxygenase 1 and 2 (COX 1 & 2), which leads to impairment of prostaglandin synthesis and a subsequent decrease in inflammation and pain. Inhibition of prostaglandin synthesis can also cause sodium and water retention and a decrease in renal blood flow and glomerular filtration rate. The newer selective COX-2 inhibitor NSAIDs (celecoxib, rofecoxib) have similar effects on renal function as do the traditional NSAIDs, and should also be avoided. 29 This is a critical point for patients and providers alike as many think that the COX-2 drugs are relatively free of side effects and, thus, they are prescribed and used ubiquitously. These untoward effects of NSAIDs are even more pronounced in the elderly population with HF. In two large observational studies, NSAID use was associated with a 10-fold adjusted relative risk for hospitalization with HF. 30, 31 Corticosteroid medications are also to be avoided or used sparingly because of their potential for hypertension and edema due to sodium and fluid retention.
Heart failure providers need to be vigilant about asking about over-the-counter medications at each visit and always inquire about NSAID use if patients suddenly become resistant to their standard diuretic dose or there is a sudden deterioration in renal function or an abrupt weight gain. NSAIDs are often prescribed by other health providers; thus, HF patients should be taught to be their own advocates by telling them to advise other providers of their inability to take NSAIDs. A written handout for patients that lists all the available NSAIDs is very helpful. If your facility uses an electronic medical record, a notation on the front page about avoiding NSAIDs is an additional safety measure.
Situations may occur where use of a corticosteroid or NSAID is unavoidable. If used, they should be used for the briefest time possible and at the lowest dose possible with frequent monitoring of weight and renal function.
Acute Pain
Common causes of acute pain in HF patients are gout, migraines, musculoskeletal pain (strain, sprain, fracture), or postoperative pain. Assess the level of the patient's pain and start at that particular step of the WHO ladder (ie, do not start at Step 1 if patients are in severe pain). For mild pain, acetaminophen (not to exceed 4000 mg daily) is a first-line choice. An acetaminophen dose of 650 mg is approximately equal to 30 mg of codeine. Acetaminophen can also be added to any opioid for additive effects and to minimally decrease the opioid dose. The majority of patients can be managed with acetaminophencodeine combinations.
Acute gout episodes are fairly common in HF patients, especially those on high dose diuretic therapy. These episodes are problematic as patients often seek care on an urgent basis with primary care or rheumatology providers, who usually prescribe NSAIDs. As noted, patients need to understand that these drugs are not good choices for them. For acute gout episodes, colchicine as tolerated (usually 1.2 mg initially followed by 0.6 mg b.i.d.) can be used to decrease the pain and inflammation; often, however, an opioid or an opioid-acetaminophen combination is needed as the pain can become quite severe. Allopurinol should not be started or increased during acute episodes as it could precipitate another gout attack. Patients prone to gout should also be taught to avoid triggers such as trauma to known affected joints, binge alcohol ingestion, fasting, and a very low carbohydrate diet. 32 Heart failure patients with persistent migraines should try prophylactic therapy (often HF patients note a decrease in migraines after being on a beta blocker for their HF). Drugs in the triptan class (eg, sumitriptan) should be used with caution in HF patients because of possible untoward effects such as palpitations, syncope, and arrhythmias. Patients with ischemic heart disease should also avoid this class of drugs because of the possible precipitation of angina.
Chronic Pain
Chronic pain is an exceedingly common problem for patients with HF. The American Chronic Pain Association estimates that one in three Americans (approximately 50 million people) suffers from some type of chronic pain. 33 Common causes of chronic pain in HF patients are musculoskeletal problems and neuropathy.
For musculoskeletal problems, following the WHO ladder, acetaminophen is a good first choice for mild pain. Topical capsaicin cream, which works by depleting Substance P, is helpful for some patients; however, it requires t.i.d. to q.i.d. dosing and it takes several weeks for full effects to be realized. Many patients with arthritis take glucosamine supplements for pain relief. Glucosamine may reduce pain, have mild anti-inflammatory effects, improve range of motion in affected joints, and slow or halt the progression of osteoarthritis. 34 Three recent meta-analyses have been done on glucosamine-two 35, 36 noted some efficacy with this preparation and one 37 noted that more research was needed. Glucosamine generally has few interactions with other medications; however diuretics may decrease the effectiveness of glucosamine. 38 Diligent monitoring of glucose levels is needed in the diabetic as glucosamine may increase resistance to insulin. 38 Further information on the efficacy of glucosamine will be forthcoming in 2007 from the GAIT study (Glucosamine-Chondroitin Arthritis Intervention Trial), which is sponsored by several federal agencies. 39 Neuropathic pain commonly occurs in HF patients with diabetes or cancer. It is characterized by sharp, shooting, electric-shock-like sensations, can be quite severe in intensity, and is often very difficult to control. Adjuvant medications (Table 6) , especially TCAs and anticonvulsants, are used to treat this pain; these drugs alter, attenuate or otherwise modulate pain perception. 26 They may be used alone or in combination with opioid or nonopioid drugs to achieve pain relief. New surgical techniques, such as peripheral nerve decompression, have shown promise for treatment of some peripheral neuropathies. 40 There are a few important issues related to the use of certain adjuvants in HF patients. The TCAs have anticholinergic side effects (orthostatic hypotension, dry mouth, dizziness) that may be intolerable to HF patients, especially elderly patients. Dosing for pain is usually less than that for depression, so side effects may be lessened. Desipiramine may be the best choice in this category as it has fewer of the anticholinergic side effects and also less cardiotoxicity potential. 26 Selective serotonin uptake inhibitors (SSRIs) have not been shown to be very effective against pain. 7 Of the anticonvulsants, gabapentin is the most commonly used as it has a low side effect profile and is very effective for neuropathic pain although some patients may require dosing as high as 3600 mg/day. Local anesthestics are second-line drugs for those who have not achieved relief with TCAs and anticonvulsants. Mexilitene, an oral local anesthetic, has multiple cardiac side effects and should not be used for pain management in HF patients. 26 If the patient's pain cannot be controlled with standard pharmacologic and nonpharmacologic measures, referral to a pain management specialist is warranted. Patients with uncontrolled pain also frequently develop depression, anxiety, and significant sleep disorders, all of which also may need specific interventions until the pain is under better control.
Summary
Pain is one of the most common reasons people seek medical care and thus is a frequent complaint during a HF visit. Believing the patient's report of pain is the first step of an effective treatment strategy. Standard pain algorithms need modification in HF patients owing to their inability to use NSAIDs and corticosteroid medications. Use of acetaminophen and opioids, avoiding certain deleterious interventions, and including nonpharmacologic strategies are key to effective pain management in this population. No matter how well we manage patients' HF, their quality of life will be poor unless we also address their coexisting pain syndromes. 
